-

City of Hope Scientists Showcase New Findings at the 2020 AACR Virtual Annual Meeting II

These important proof-of-concept studies could one day lead to new real-time diagnostic imaging techniques and the identification of genomic biomarkers that predict treatment results – innovations that will improve health outcomes for cancer patients

DUARTE, Calif.--(BUSINESS WIRE)--City of Hope scientists will showcase research at the AACR Virtual Annual Meeting II that could one day lead to real-time diagnostic imaging and leading-edge genomic profiling that improve health outcomes for cancer patients, and much more.

“Innovative cancer immunotherapy and lifesaving precision medicine are areas City of Hope has doubled down on. In the years to come, we expect to yield research results that could be developed into therapies and practices that transform the delivery of cancer care,” said Michael Caligiuri, president of City of Hope National Medical Center, former American Association for Cancer Research president and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair.

AACR’s second virtual session will take place from June 22-24. More than 61,000 people from 140 countries registered to attend the first virtual session in April. The multidisciplinary meeting program will highlight the best cancer science and medicine in the world.

Using imaging biomarkers to deliver personalized care

Radiomic prediction of survival in recurrent high-grade glioma patients treated with CAR T-cell therapy

City of Hope physician-scientists are developing accurate theranostics (therapy + diagnostics) to deliver precision medicine in cancer care. Ammar Chaudhry, M.D., a diagnostic radiologist at City of Hope, and colleagues used machine learning models to compare the “survival prediction performance” of patients who have a type of brain tumor called high-grade glioma. Having accurate survival prediction performance equips doctors with the data necessary to determine the best treatment options for each patient. Physician-scientists performed baseline imaging, surgically removed the brain cancer and then delivered CAR T cell therapy. Using machine learning, the researchers found that labeling tumor voxels (3D pixels) as non-enhancing tumor (NET) was significantly more accurate at predicting prognosis than using other labeling methods. Further research is needed to make this model more robust.

Precision medicine: Full DNA and RNA genome profiling of all cancer patients

Identifying the genomic correlates of clinical benefit (CB) from immunotherapies (IO) and vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKI) in metastatic renal cell carcinoma (mRCC)

City of Hope is working toward profiling the genomes of all patients to provide the most effective, personalized treatment. Sumanta Pal, M.D., co-director of City of Hope’s Kidney Cancer Program, led a study that looked at tumor-specific alterations resulting from specific cancer treatments. Using a proprietary tool that analyzes all DNA-coding regions, the City of Hope researchers found that having an abundance of mutations at the very end of certain RNA (known as telomeres or TERT promoter mutations) may be a biomarker that predicts immunotherapy will not work for a patient. Understanding how useful certain treatments will be for a specific patient can help physicians weed out ineffective treatments so that time and money can be spent on treatments that have a chance of bringing the patient into remission. Because the sample size was 58 patients, this research warrants further investigation with larger prospective cohorts.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is the highest ranked cancer hospital in the West, according to U.S. News & World Report’s Best Hospitals: Specialty Ranking. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

Contacts

Zen Vuong
626-409-9367
zvuong@coh.org

City of Hope


Release Summary
City of Hope scientists showcase research at the AACR Virtual Annual Meeting II that will improve health outcomes for cancer patients.
Release Versions
Hashtags

Contacts

Zen Vuong
626-409-9367
zvuong@coh.org

Social Media Profiles
More News From City of Hope

Study Reveals How Gut Bacteria and Diet Can Reprogram Fat to Burn More Energy

LOS ANGELES--(BUSINESS WIRE)--Scientists at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. and a leading research center for diabetes, the Broad Institute and Keio University have discovered how specific gut bacteria work together with diet to flip a metabolic switch — transforming energy‑storing white fat into calorie‑burning beige fat in mice. The study, published today in Nature, shows that a low‑protein diet activates a precise se...

City of Hope®: Early Diagnostics Will Stem the Surge of Colorectal Cancer in Younger Adults

LOS ANGELES--(BUSINESS WIRE)--Experts at City of Hope, one of the nation’s largest and most advanced cancer research and treatment organizations, say the surge in colorectal cancer in people under 50 — often compounded by delayed diagnoses and misinterpreted symptoms — requires age-specific research, treatments, education, and diagnostic tools. A blood test under development at City of Hope could become a breakthrough for detecting the disease early, making it part of an annual exam. Colorectal...

Second Annual $1 Million Stephenson Global Prize Now Open for Nominations

LOS ANGELES--(BUSINESS WIRE)--The Stephenson Global Prize, a $1 million award for innovation in pancreatic cancer research, has opened its second call for nominations. Awarded annually, the Prize recognizes visionary scientific leaders whose work is fundamentally changing the trajectory of pancreatic cancer research. Nominations are now open through May 1, 2026. The Stephenson Global Prize is part of a philanthropic program launched by A. Emmet Stephenson Jr., and Tessa Stephenson Brand. Their...
Back to Newsroom